Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.16 (
calcineurin
)
17,112
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Dysregulation of phosphatidyl inositol signaling occurs in many cancers and other disorders. The lipid and
protein phosphatase
, PTEN (Phosphatase and Tensin homology protein on chromosome 10), is a known tumor suppressor whose function is frequently lost in various malignancies due to mutations in the coding region or genomic deletions. Recently, another lipid phosphatase, Inositol Polyphosphate 4-phosphatase type II (
INPP4B
), has emerged as a potential tumor suppressor in prostate, breast, and ovarian cancers and possibly in leukemia. We will review its structure and function, crosstalk with androgen receptor signaling, and regulation of
INPP4B
expression, as well as existing data about its role in cancer.
...
PMID:INPP4B: the new kid on the PI3K block. 2148 59
The phosphatidylinositol 3-kinase (PI3K) pathway plays a pivotal role in the maintenance of processes such as cell growth, proliferation, survival, and metabolism in all cells and tissues. Dysregulation of the PI3K/Akt signaling pathway occurs in patients with many cancers and other disorders. This aberrant activation of PI3K/Akt pathway is primarily caused by loss of function of all negative controllers known as inositol polyphosphate phosphatases and phosphoprotein phosphatases. Recent studies provided evidence of distinct functions of the four main phosphatases-phosphatase and tensin homologue deleted on chromosome 10 (PTEN), Src homology 2-containing inositol 5'-phosphatase (SHIP), inositol polyphosphate 4-phosphatase type II (
INPP4B
), and protein phosphatase 2A (
PP2A
)-in different tissues with respect to regulation of cancer development. We will review the structures and functions of PTEN, SHIP,
INPP4B
, and
PP2A
phosphatases in suppressing cancer progression and their deregulation in cancer and highlight recent advances in our understanding of the PI3K/Akt signaling axis.
...
PMID:Phosphatases: the new brakes for cancer development? 2212 80
The tumor suppressor
INPP4B
is an important regulator of phosphatidyl-inositol signaling in the cell. Reduced
INPP4B
expression is associated with poor outcomes for breast, prostate, and ovarian cancer patients.
INPP4B
contains a CX5R catalytic motif characteristic of dual-specificity phosphatases, such as PTEN. Lipid phosphatase activity of
INPP4B
has previously been described. In this report we show that
INPP4B
can dephosphorylate para-nitrophenyl phosphate (pNPP) and 6,8-difluoro-4-methylumbelliferyl (DiFMUP), synthetic phosphotyrosine analogs, suggesting that
INPP4B
has protein tyrosine phosphatase (PTP) activity. Using mutagenesis, we examined the functional role of specific amino acids within the
INPP4B
C842KSAKDR catalytic site. The K843M mutant displayed increased pNPP hydrolysis, the K846M mutant lost lipid phosphatase activity with no effect on PTP activity, and the D847E substitution ablated PTP activity and significantly reduced lipid phosphatase activity. Further, we show that
INPP4B
but not PTEN is able to reduce tyrosine phosphorylation of Akt1 and both the lipid and PTP activity of
INPP4B
likely contribute to the reduction of Akt1 phosphorylation. Taken together our data identified key residues in the
INPP4B
catalytic domain associated with lipid and
protein phosphatase
activities and found a robust downstream target regulated by
INPP4B
but not PTEN.
...
PMID:Determinants of the tumor suppressor INPP4B protein and lipid phosphatase activities. 2407 Jun 12
Inositol polyphosphate 4-phosphatase type II (
INPP4B
) negatively regulates phosphatidylinositol 3-kinase signaling and is a tumor suppressor in some types of cancers. However, we have found that it is frequently upregulated in human colon cancer cells. Here we show that silencing of
INPP4B
blocks activation of Akt and serum- and glucocorticoid-regulated kinase 3 (SGK3), inhibits colon cancer cell proliferation and retards colon cancer xenograft growth. Conversely, overexpression of
INPP4B
increases proliferation and triggers anchorage-independent growth of normal colon epithelial cells. Moreover, we demonstrate that the effect of
INPP4B
on Akt and SGK3 is associated with inactivation of phosphate and tensin homolog through its
protein phosphatase
activity and that the increase in
INPP4B
is due to Ets-1-mediated transcriptional upregulation in colon cancer cells. Collectively, these results suggest that
INPP4B
may function as an oncogenic driver in colon cancer, with potential implications for targeting
INPP4B
as a novel approach to treat this disease.
...
PMID:INPP4B is an oncogenic regulator in human colon cancer. 2641 69